Real-World Use of Bone-Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer
Volume: 114, Issue: 3, Pages: 419 - 426
Published: Oct 1, 2021
Abstract
Bone-modifying agent (BMA) therapy is recommended for metastatic castration-resistant prostate cancer but not metastatic castration-sensitive prostate cancer (mCSPC). BMA treatment in mCSPC may therefore constitute overuse.In this retrospective cohort study using linked Surveillance, Epidemiology, and End Results-Medicare data, we included patients diagnosed with stage IV prostate adenocarcinoma from 2007 to 2015 who were 66 years of age or...
Paper Details
Title
Real-World Use of Bone-Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer
Published Date
Oct 1, 2021
Volume
114
Issue
3
Pages
419 - 426
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History